The 90% effective dose (ED90) of remimazolam for inhibiting responses to the insertion of a duodenoscope during ERCP.
90% effective dose
Alfentanil
ERCP
Remimazolam
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
21
08
2023
accepted:
06
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Compared to midazolam, remimazolam has a faster onset and offset of hypnotic effect, as well as cardiorespiratory stability, this study aims to determine the 90% effective dose (ED90) of remimazolam to inhibit responses to insertion of a duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP). A dose-response study was carried out undergoing ERCP who received remimazolam-alfentanil anesthesia using 10 µg/kg of alfentanil between September 2021 and November 2021. The initial dose of remimazolam was 0.2 mg/kg. The dose was then decided based on the responses of earlier patients by exploiting the sequential ascend and descend according to a 9: 1 biased coin design. Upon failure, the dose of remimazolam was increased by 0.025 mg/kg in the next patient. When the insertion was successful, the succeeding patient was randomized to an identical dose or a dose that was lower by 0.025 mg/kg.The ED90 of remimazolam for inhibiting responses to the insertion of a duodenoscope during ERCP was calculated. Adverse events and complications of remimazolam were recorded. A total of 55 elderly patients (age > 65) were included in the study. 45 successfully anesthetized patients, and 10 unsuccessfully. The ED90 of remimazolam was 0.300 mg/kg (95% CI = 0.287-0.320). ED95 was 0.315 (95% CI = 0.312-0.323) and ED99 was 0.323 (95% CI = 0.323-0.325). Among the patients, 9 patients developed hypotension, 2 patients developed bradycardia and 1 patient developed tachycardia, and hypoxia occurred in 2 patients. A loading dose of 0.300 mg / kg of remimazolam for elderly patients undergoing ERCP can safely, effectively, and quickly induce patients to fall asleep and inhibit responses to the insertion of a duodenoscope. The study protocol was registered at the website ClinicalTrials.gov on 22/09/2021(NCT05053763).
Sections du résumé
BACKGROUND
BACKGROUND
Compared to midazolam, remimazolam has a faster onset and offset of hypnotic effect, as well as cardiorespiratory stability, this study aims to determine the 90% effective dose (ED90) of remimazolam to inhibit responses to insertion of a duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
METHODS
METHODS
A dose-response study was carried out undergoing ERCP who received remimazolam-alfentanil anesthesia using 10 µg/kg of alfentanil between September 2021 and November 2021. The initial dose of remimazolam was 0.2 mg/kg. The dose was then decided based on the responses of earlier patients by exploiting the sequential ascend and descend according to a 9: 1 biased coin design. Upon failure, the dose of remimazolam was increased by 0.025 mg/kg in the next patient. When the insertion was successful, the succeeding patient was randomized to an identical dose or a dose that was lower by 0.025 mg/kg.The ED90 of remimazolam for inhibiting responses to the insertion of a duodenoscope during ERCP was calculated. Adverse events and complications of remimazolam were recorded.
RESULTS
RESULTS
A total of 55 elderly patients (age > 65) were included in the study. 45 successfully anesthetized patients, and 10 unsuccessfully. The ED90 of remimazolam was 0.300 mg/kg (95% CI = 0.287-0.320). ED95 was 0.315 (95% CI = 0.312-0.323) and ED99 was 0.323 (95% CI = 0.323-0.325). Among the patients, 9 patients developed hypotension, 2 patients developed bradycardia and 1 patient developed tachycardia, and hypoxia occurred in 2 patients.
CONCLUSIONS
CONCLUSIONS
A loading dose of 0.300 mg / kg of remimazolam for elderly patients undergoing ERCP can safely, effectively, and quickly induce patients to fall asleep and inhibit responses to the insertion of a duodenoscope.
TRIAL REGISTRATION
BACKGROUND
The study protocol was registered at the website ClinicalTrials.gov on 22/09/2021(NCT05053763).
Identifiants
pubmed: 38745175
doi: 10.1186/s12871-024-02554-1
pii: 10.1186/s12871-024-02554-1
doi:
Banques de données
ClinicalTrials.gov
['NCT05053763']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
174Informations de copyright
© 2024. The Author(s).
Références
Cho CM. The future of Endoscopic Retrograde Cholangiopancreatography in Korea. Gut Liver. 2021;15(6):795–6.
doi: 10.5009/gnl210504
pubmed: 34782488
pmcid: 8593509
Park CH, Park SW, Hyun B, et al. Efficacy and safety of etomidate-based sedation compared with propofol-based sedation during ERCP in low-risk patients: a double-blind, randomized, noninferiority trial. Gastrointest Endosc. 2018;87(1):174–84.
doi: 10.1016/j.gie.2017.05.050
pubmed: 28610897
Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427–e4376.
doi: 10.1016/j.gie.2018.04.2351
pubmed: 29723512
Chen SH, Yuan TM, Zhang J, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021;36(2):474–81.
doi: 10.1111/jgh.15188
pubmed: 32677707
Lee A, Shirley M, Remimazolam. A review in Procedural Sedation. Drugs. 2021;81(10):1193–201.
doi: 10.1007/s40265-021-01544-8
pubmed: 34196946
Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506–11.
doi: 10.1097/ACO.0000000000000877
pubmed: 32530890
Kim KM. Remimazolam: pharmacological characteristics and clinical applications in anesthesiology. Anesth Pain Med (Seoul). 2022;17(1):1–11. https://doi.org/10.17085/apm.21115 .
doi: 10.17085/apm.21115
pubmed: 35139608
Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34(4):543–53.
doi: 10.1007/s00540-020-02788-6
pubmed: 32417976
Pantos MM, Kennedy DR, Nemec EC. Remimazolam: a novel option for procedural sedation in high risk patients. J Pharm Pract. 2021:8971900211027303.
White PF. Remimazolam - can it become a cost-effective alternative to propofol for intravenous anesthesia and sedation? J Clin Anesth. 2023;84:110977.
doi: 10.1016/j.jclinane.2022.110977
pubmed: 36401885
Dong SA, Guo Y, Liu SS, Wu LL, Wu LN, Song K, Wang JH, Chen HR, Li WZ, Li HX, Zhang L, Yu JB. A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures. J Clin Anesth. 2023;86:111077.
doi: 10.1016/j.jclinane.2023.111077
pubmed: 36764022
Smith ZL, Das KK, Kushnir VM. Anesthesia-administered sedation for endoscopic retrograde cholangiopancreatography: monitored anesthesia care or general endotracheal anesthesia? Curr Opin Anaesthesiol. 2019;32(4):531–7.
doi: 10.1097/ACO.0000000000000741
pubmed: 30994476
Dhaliwal A, Dhindsa BS, Saghir SM, et al. Choice of sedation in endoscopic retrograde cholangiopancreatography: is monitored anesthesia care as safe as general anesthesia? A systematic review and meta-analysis. Ann Gastroenterol. 2021;34(6):879–87.
pubmed: 34815655
pmcid: 8596211
Cheriyan DG, Byrne MF. Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. World J Gastroenterol. 2014;20(18):5171–6.
doi: 10.3748/wjg.v20.i18.5171
pubmed: 24833847
pmcid: 4017032
Liu M, Sun Y, Zhou L, Feng K, Wang T, Feng X. The median effective dose and Bispectral Index of Remimazolam Tosilate for Anesthesia induction in Elderly patients: an Up-and-down sequential allocation trial. Clin Interv Aging. 2022;17:837–43.
doi: 10.2147/CIA.S364222
pubmed: 35620021
pmcid: 9129099
Yu AL, Critchley LA, Lee A, Gin T. Alfentanil dosage when inserting the classic laryngeal mask airway. Anesthesiology. 2006;105(4):684–8.
doi: 10.1097/00000542-200610000-00012
pubmed: 17006065
George RB, McKeen D, Columb MO, Habib AS. Up-down determination of the 90% effective dose of phenylephrine for the treatment of spinal anesthesia-induced hypotension in parturients undergoing cesarean delivery. Anesth Analg. 2010;110(1):154–8.
doi: 10.1213/ANE.0b013e3181c30b72
pubmed: 19910625